

Sales update April 2024 YTD

May 2024

Galenica Group



Pleasing sales growth in the first 4 months of 2024

Net sales (in million CHF) +4.8% 1'256 +5.6% 1'198 1′036 981 +4.5% ■ 04/2023 543 519 ■ 04/2024 Galenica Group Products & Care Logistics & IT


👼 Galenica

Galenica Group Sales growth in all business areas

Net sales (in million CHF)	2024	2023	change
Local Pharmacies	430	412	+4.3%
Pharmacies at Home	26	25	+2.1%
Retail (B2C)	456	438	+4.2%
Products & Brands	64	61	+5.2%
Services for Professionals	27	25	+11.7%
Professionals (B2B)	91	85	+7.1%
Products & Care	543	519	+4.5%
Wholesale	992	941	+5.4%
Logistics & IT Services	52	47	+11.6%
Logistics & IT	1′036	981	+5.6%
Corporate and eliminations	-323	-302	
Galenica Group	1′256	1′198	+4.8%

Retail B2C Pleasing organic sales growth

Net sales (in million CHF)



1) The effect of net expansion is calculated only including point of sales without a full year period comparison (acquisitions, openings and closure of pharmacies)

 Mandatory price reductions of medications reimbursed by health insurers of the specialities list (SL/LS) released by the Federal Office of Public Health (FOPH), calculated based on volumes of previous period




Products & Brands



Market share gains and strong international growth

Net sales (in million CHF)




1) Expansion impact related to acquisition of Padma AG in Jan 2023, the effect of net expansion is calculated only including business activities without a full year period comparison (acquisitions and new license agreements)

2) © IQVIA Switzerland - Consumer Health market April 2024 (without Covid-19 self-tests)

Services for professionals

Strong sales growth in elderly care segment

Net sales (in million CHF)






Strong growth with services for homecare organisations and nursing homes



Wholesale Further market share gains

Net sales (in million CHF)






1) Mandatory price reductions of medications reimbursed by health insurers of the specialities list (SL/LS) released by the Federal Office of Public Health (FOPH), calculated based on volumes of previous period

Logistics & IT Services Pleasing sales growth

Net sales (in million CHF)



*G*alenica


Further growth with IT services and pre-wholesale distribution







Swiss pharmaceutical market 04/2024



Medicines Swissmedic lists A, B, D, sold from suppliers and wholesalers to hospitals, physicians, pharmacies and drugstores © IQVIA Switzerland - Swiss pharmaceutical market April 2024



Swiss pharmaceutical market Solid growth in four first months of 2024




Source: APO/SD/DRO/SPI Index, Swissmedic A, B, D

Medicines Swissmedic lists A, B, D, sold from suppliers and wholesalers to hospitals, physicians, pharmacies and drugstores © IQVIA Switzerland - Swiss pharmaceutical market April 2024

Swiss consumer healthcare market 04/2024





Source: IQVIA PharmaTrend for pharmacies and drugstores in Switzerland, streetprices © IQVIA Switzerland - Consumer Health market April 2024 (without Covid-19 self-tests)



Disclaimer

Disclaimer Galenica

Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this presentation as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its of their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements, which speak only as of the date of this presentation.

Disclaimer IQVIA © 2024, IQVIA AG

All rights reserved. The information may not be duplicated, stored, processed further, nor be made accessible in whole or in part to any third party without prior express and valid written permission of IQVIA AG. Terms used in connection with data/figures such as "patient", "doctor", "medical practice", "prescriber", or "pharmacy" do not designate any personal data but exclusively anonymous information (according to applicable, valid data protection laws).

IQVIA utilizes highly sophisticated technologies and methods in order to ensure that all its Information Services meet the applicable data protection requirements, regardless of the way data are combined.